FDA Brief

Warning letters Drugs

FDA warning letter to

AriBio H&B Co., Ltd.

High riskIssued Oct 8, 2021Posted Oct 19, 2021Center for Drug Evaluation and Research | CDER

FDA warns AriBio H&B over subpotent Hand Sanitizer Original labeled 70% ethanol but tested at 58%, plus misbranding.

What happened

FDA tested a batch of Hand Sanitizer Original that was detained and refused admission at the U.S. border; the product was labeled as made at AriBio H&B's facility. The label said 70% ethanol, but FDA found an average of only 58% w/v. FDA also found the label's dietary-supplement wording false or misleading and no U.S. adverse-event contact; after a November 20, 2020 teleconference, FDA said the firm did not provide methanol test method documentation or a rationale for its ethanol test method.

What FDA found

  1. FDA lab testing found the hand sanitizer labeled as 70% ethanol contained only 58% w/v ethanol on average.

    section 501(c) FD&C Act, 21 U.S.C. 351(c)
  2. FDA said the subpotency and the firm's inadequate response to the November 20, 2020 teleconference show that quality assurance is not working under CGMP.

    section 501(a)(2)(B) FD&C Act, 21 U.S.C. 351(a)(2)(B)
  3. The firm did not provide documentation of its methanol content test method or a scientific rationale for its ethanol content test method, and FDA said incoming raw materials were not adequately tested.

    21 CFR 211.84
  4. The label says “REDLAB Korea NO1 Dietary Supplement” and “H&B aribio Korea NO1 Dietary Supplement,” which FDA called false or misleading because the product is a topical antiseptic, not an ingested dietary supplement.

    section 502(a) FD&C Act, 21 U.S.C. 352(a)
  5. The label does not give a U.S. address or U.S. telephone number for reporting a serious adverse event.

    section 502(x) FD&C Act, 21 U.S.C. 352(x)

What FDA wants

FDA asks AriBio H&B to respond in writing within 15 working days with a follow-up investigation into the low ethanol content, lists of raw materials and suppliers, a reconciliation of U.S.-shipped batches, batch records, and the methanol content test method. FDA also strongly recommends a qualified CGMP consultant if the firm intends to resume making drugs for the U.S. market.

Who should pay attention

  • brands or distributors that bought hand sanitizer from this manufacturer
  • U.S. importers and retailers of consumer hand sanitizers
  • contract manufacturers and suppliers of ethanol raw materials

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Macau-Union Pharmaceutical Limited

    Macau-Union Pharmaceutical failed CGMP and sold unapproved, misbranded Bamboo Pharmacy OTC pain rubs in the U.S.

    High risk
  2. ImprimisRx NJ

    FDA found insanitary sterile compounding and subpotent timolol-latanoprost eye drops at ImprimisRx NJ.

    High risk
  3. Shuzy Rock Inc.

    FDA warns Shuzy Rock Inc. of adulterated hand sanitizers made under insanitary conditions and found below labeled alcohol strength.

    High risk
  4. Guangzhou Zhongkebaishi Health Industry Co., Ltd.

    Guangzhou Zhongkebaishi's Hand Sanitizer Gel, labeled 75% ethanol, tested at 51% and was refused US import.

    High risk